Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 8,279 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Healthy
Interventions: Intravenous diclofenac sodium (DIC075V); Drug
Lead sponsor: Javelin Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Miramar, Florida • Baltimore, Maryland

Conditions: Muscular Atrophy, Spinal
Interventions: Placebo, Risdiplam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Palo Alto, California • New York, New York

Conditions: Cerebral Palsy, Prematurity
Interventions: Not listed
Lead sponsor: Charles R. Neal,; Other
Eligibility: Up to 2 Months
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Interventions: 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Vincristine Sulfate; Radiation · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 213
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 151 more

Conditions: Achondroplasia
Interventions: Navepegritide, Placebo for Navepegritide; Drug
Lead sponsor: Ascendis Pharma A/S; Industry
Eligibility: 0 Years to 2 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Saint Paul, Minnesota • Houston, Texas • Madison, Wisconsin

Conditions: Leukemia, Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions: Leukapheresis; Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Meditation, Control Group
Interventions: Calm Meditation, Educational Podcast Control; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 40 Years to 64 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary, Urinary Tract Procedure
Interventions: Ureteroscope system, Laser system; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: Not listed
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Phoenix, Arizona • Miami, Florida • Tampa, Florida + 2 more

Conditions: Cyclin-Dependent Kinase-Like 5 Deficiency Disorder
Interventions: No intervention; observational; Other
Lead sponsor: Loulou Foundation; Other
Eligibility: Up to 55 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 9
States / cities: Los Angeles, California • Aurora, Colorado • Norcross, Georgia + 6 more

Conditions: Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease, CAD, CVD, CHD
Interventions: Corus CAD (ASGES); Diagnostic Test
Lead sponsor: CardioDx; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Recurrent Wheezing, Wheezing Lower Respiratory Illness
Interventions: OM-85, Placebo; Drug
Lead sponsor: OM Pharma SA; Industry
Eligibility: 6 Months to 72 Months
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 31
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more

Conditions: Bipolar Disorder
Interventions: Lithium carbonate, Valproate, Risperidone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 15 Years
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Aging, Cognitive Impairment, Sleep
Interventions: Sleep health and mindfulness intervention; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 55 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: PreDiabetes, Obesity, Childhood
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 8 Years to 22 Years
Enrollment: 772 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Opiate Withdrawal Syndrome
Interventions: Methadone; Drug
Lead sponsor: Kevin Watt; Other
Eligibility: 91 Days to 18 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: St. Petersburg, Florida • Kansas City, Kansas • Ann Arbor, Michigan + 2 more

Conditions: Normal Physiology
Interventions: Pupillometry, Light box exposure; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Attention Deficit/Hyperactivity Disorder
Interventions: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo; Drug · Other
Lead sponsor: Corium, Inc.; Industry
Eligibility: 4 Years to 12 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 20
States / cities: Little Rock, Arkansas • Anaheim, California • Centennial, Colorado + 17 more

Conditions: Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions: Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care; Device · Behavioral · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 15 Years to 40 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: IM Pneumococcal, meningococcal, or flu vaccine; Biological
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Age
Interventions: Lower Protein, Medium Protein, Higher Protein; Other
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Breast Cancer, Ovarian Cancer, Hereditary Cancer Syndrome
Interventions: ELISABETH Evidence-Informed Program (EIP); Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza
Interventions: Tamiflu; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Up to 365 Days
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 38
States / cities: Little Rock, Arkansas • Los Angeles, California • Oakland, California + 32 more

Conditions: Diabetic Retinopathy, Macular Degeneration, Pathologic Neovascularization, Retinal Disease
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Infections, Clostridium Difficile
Interventions: Blood sampling, Stool sample collection; Procedure · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Little Rock, Arkansas • Boston, Massachusetts • Houston, Texas

Search by objective public record fields.

Study to Assess Effects of Age, Weight, and Body Composition on the Pharmacokinetics of IV Diclofenac Sodium

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

Study of Generalized Movements for Early Prediction of Cerebral Palsy

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia

Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

A Brief App-based Mobile Health and Well-being Intervention Among Middle-aged Adults

Stone and Laser Therapies Post-Market Study (SALT)

Observational Study in Patients With Cyclin-dependent Kinase-like 5 Deficiency Disorder

Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test

A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents

Leveraging Social Networks to Improve Sleep and Mindfulness Among Older Adults in Residential Housing Facilities

Conventional and Metabolomic Predictors of Prediabetes & Insulin Resistance

Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal

Impact of Sex and Age on Non-visual Light Input That Affects Sleep and Circadian Rhythms

An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD

EPI-MINN: Targeting Cognition and Motivation - National

An Open Label Study of IgG Fc Glycan Composition in Human Immunity

Dietary Protein Requirement of Elderly Men and Women

EHR Intervention to Increase HBOC Genetic Testing

A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza

Screening for Studies on Retinovascular Diseases

Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI)